This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
|Treatment||Baricitinib, TNF Inhibitor|
|Clinical Study Identifier||NCT03915964|
|Sponsor||Eli Lilly and Company|
|Last Modified on||25 November 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.